Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome

Robert L. Gustofson, Frederick W. Larsen, Mark R. Bush, James Segars

Research output: Contribution to journalArticle

Abstract

Forty-seven patients at high risk for ovarian hyperstimulation syndrome because of markedly elevated serum E 2 levels on either long-luteal or microdose flare leuprolide acetate regimens were treated with ganirelix acetate. Despite being pretreated with GnRH agonist and without withholding gonadotropins, serum E 2 decreased by 49.5% and 41.0% of pretreatment values (long luteal and microdose flare, respectively) after initiation of ganirelix, and 68.1% of the patients became pregnant.

Original languageEnglish (US)
Pages (from-to)251-254
Number of pages4
JournalFertility and Sterility
Volume85
Issue number1
DOIs
StatePublished - Jan 2006
Externally publishedYes

Fingerprint

Ovarian Hyperstimulation Syndrome
Hormone Antagonists
Corpus Luteum
Gonadotropin-Releasing Hormone
Leuprolide
Serum
Gonadotropins
Therapeutics
ganirelix

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome. / Gustofson, Robert L.; Larsen, Frederick W.; Bush, Mark R.; Segars, James.

In: Fertility and Sterility, Vol. 85, No. 1, 01.2006, p. 251-254.

Research output: Contribution to journalArticle

@article{ef7fce66125d476283b146d46e625823,
title = "Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome",
abstract = "Forty-seven patients at high risk for ovarian hyperstimulation syndrome because of markedly elevated serum E 2 levels on either long-luteal or microdose flare leuprolide acetate regimens were treated with ganirelix acetate. Despite being pretreated with GnRH agonist and without withholding gonadotropins, serum E 2 decreased by 49.5{\%} and 41.0{\%} of pretreatment values (long luteal and microdose flare, respectively) after initiation of ganirelix, and 68.1{\%} of the patients became pregnant.",
author = "Gustofson, {Robert L.} and Larsen, {Frederick W.} and Bush, {Mark R.} and James Segars",
year = "2006",
month = "1",
doi = "10.1016/j.fertnstert.2005.07.1291",
language = "English (US)",
volume = "85",
pages = "251--254",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome

AU - Gustofson, Robert L.

AU - Larsen, Frederick W.

AU - Bush, Mark R.

AU - Segars, James

PY - 2006/1

Y1 - 2006/1

N2 - Forty-seven patients at high risk for ovarian hyperstimulation syndrome because of markedly elevated serum E 2 levels on either long-luteal or microdose flare leuprolide acetate regimens were treated with ganirelix acetate. Despite being pretreated with GnRH agonist and without withholding gonadotropins, serum E 2 decreased by 49.5% and 41.0% of pretreatment values (long luteal and microdose flare, respectively) after initiation of ganirelix, and 68.1% of the patients became pregnant.

AB - Forty-seven patients at high risk for ovarian hyperstimulation syndrome because of markedly elevated serum E 2 levels on either long-luteal or microdose flare leuprolide acetate regimens were treated with ganirelix acetate. Despite being pretreated with GnRH agonist and without withholding gonadotropins, serum E 2 decreased by 49.5% and 41.0% of pretreatment values (long luteal and microdose flare, respectively) after initiation of ganirelix, and 68.1% of the patients became pregnant.

UR - http://www.scopus.com/inward/record.url?scp=30344433463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344433463&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2005.07.1291

DO - 10.1016/j.fertnstert.2005.07.1291

M3 - Article

VL - 85

SP - 251

EP - 254

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 1

ER -